RCM
REVB icon

Rivernorth Capital Management’s Revelation Biosciences REVB Stock Holding History

Rivernorth Capital Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$2.04M – 839
2021
Q4 		$2.04M Hold
1
– – 0.08% 189
2021
Q3 		$2.02M Hold
1
– – 0.11% 145
2021
Q2 		$2.01M Hold
1
– – 0.11% 132
2021
Q1 		$2M Hold
1
– – 0.12% 126
2020
Q4 		$1.98M Buy
+1
New +$2.02M 0.12% 130

Other funds holding REVB

Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Rivernorth Capital Management's REVB Position: Q1 2022 in Review

Rivernorth Capital Management sold out of Revelation Biosciences (REVB) in Q1 2022, closing a stake of 1 share — an estimated $2.04M sold.

Rivernorth Capital Management first reported a position in REVB in Q4 2020 and held it in 5 quarters. The position peaked at $2.04M in Q4 2021. 2 funds tracked by Wall St. Rank hold REVB as of Q1 2022.

  • Rivernorth Capital Management reported no remaining Revelation Biosciences position as of Q1 2022 after selling out during the quarter.
  • Rivernorth Capital Management sold 1 Revelation Biosciences share in Q1 2022, an estimated $2.04M.
  • Rivernorth Capital Management first reported a position in Revelation Biosciences in Q4 2020 and held it in 5 quarters.
  • Rivernorth Capital Management's Revelation Biosciences position peaked at $2.04M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.